For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

MAC15 RxPONDER trial presented at the San Antonio Breast Cancer Symposium

Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from the MAC15 RxPONDER trial presented at the 2020 San Antonio Breast Cancer Symposium. These findings may save tens of thousands of postmenopausal women each year the time, money, and harmful side effects that come with chemotherapy infusions.

More >>
 

Dr. Cheung and Dr. Hay receive bridge funding - CIHR Spring 2020 competition

Congratulations to Dr. Annette Hay, a Senior Investigator with the Canadian Cancer Trials Group and Dr. Matthew Cheung, Hematologist at Sunnybrook Health Sciences Centre. Together they received $100,000 in bridge funding in the Canadian Institutes of Health Research (CIHR) Spring 2020 competition.

More >>
 

CCTG Director Dr. Janet Dancey, elected to Canadian Academy of Health Sciences

The Canadian Cancer Trials Group (CCTG) is pleased to announce that our Director, Dr. Janet Dancey, has been elected to the Canadian Academy of Health Sciences (CAHS), which represents Canadian health sciences internationally and informs solutions that improve the health of all Canadians.

More >>
 

CCTG Announces Initiation of IND.239

CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer.

More >>
 

Planned trials

CO29

Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer (DYNAMIC III)

HD11

Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma

PAC3

Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer

SR7

Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)

Recently activated

BL13F

A Prospective Feasibility Sub-Study of BL13 - [e-PRISM]

More >>

CX6

International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer SENTICOL III

More >>

GCC1

Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumours

More >>

HDC1

Nivolumab or Brentuximab Vedotin plus AVD in Pts (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

More >>

ICC1

NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study

More >>

MA40

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)

More >>

ME15

1cm vs 2cm Wide Excision Margins for Primary Cutaneous Melanoma (MelMarT-II)

More >>

OV26

Maintenance Therapy with Olaparib and Cediranib or Olaparib Alone in Relapsed Platinum-sensitive Ovarian Cancer Following a Response to Platinum-Based Chemotherapy

More >>

PR21

PLUDO (Prostate Lutetium/Docetaxel): Study of 177Lu-PSMA-617 vs Docetaxel in Pts with Met Castration-Resistant Prostate Ca & PSMA-Positive Disease

More >>

PR22

Darolutamide Augments Standard Therapy for Localized High-Risk Prostate Cancer (DASL-HiCaP)

More >>
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>
 
TAILORx / MAC.12 breast cancer trial showed no benefit from chemotherapy for 70% of women with the most common form of breast cancer.

TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancer

Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.

More >>
 

Asking the right questions

Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.  

“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”

More >>
 

Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide

Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.

More >>
 

Publications

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

Blood advances 4: 4945 - 4954, 2020
Voso MT;Larson RA;Jones D;Marcucci G;Prior T;Krauter J;Heuser M;Lavorgna S;Nomdedeu J;Geyer SM;Walker A;Wei AH;Sierra J;Sanz MA;Brandwein JM;de Witte TM;Jansen JH;Niederwieser D;Appelbaum FR;Medeiros BC;Tallman MS;Schlenk RF;Ganser A;Amadori S;Cheng Y;Chen Y;Pallaud C;Du L;Piciocchi A;Ehninger G;Byrd J;Thiede C;Dohner K;Stone RM;Dohner H;Bloomfield CD;Lo-Coco F;

More >>

CCTG SC.24/TROG 17.06: A Randomized Phase II/III Study Comparing 24Gy in 2 Stereotactic Body Radiotherapy (SBRT) Fractions Versus 20Gy in 5 Conventional Palliative Radiotherapy (CRT) Fractions for Patients with Painful Spinal Metastases

Am Soc Therapeutic Rad Oncol , 2020
Sahgal A;Myrehaug SD;Siva S;Masucci L;Foote MC;Brundage M;Butler J;Chow E;Fehlings MG;Gabos Z;Greenspoon J;Kerba M;Lee YK;Liu MC;Maralani P;Thibault I;Wong R;Hum M;Ding K;Parulekar W;

More >>

Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia

JCO oncology practice 2020/01/27: e464 - e475, 2020
Pagel JM;Othus M;Garcia-Manero G;Fang M;Radich JP;Rizzieri DA;Marcucci G;Strickland SA;Litzow MR;Savoie ML;Spellman SR;Confer DL;Chell JW;Brown M;Medeiros BC;Sekeres MA;Lin TL;Uy GL;Powell BL;Bayer RL;Larson RA;Stone RM;Claxton D;Essell J;Luger SM;Mohan SR;Moseley A;Erba HP;Appelbaum FR;

More >>

Expanded low allele frequency RAS and BRAF V600E testing in metastatic colorectal cancer as predictive biomarkers for cetuximab in the randomized CO.17 trial (ONLINE)

Clin Cancer Res : clincanres, 2020
Loree JM;Dowers A;Tu D;Jonker D;Edelstein DL;Quinn H;Holtrup F;Price T;Zalcberg JR;Moore MJ;Karapetis CS;Callaghan CJ;Waring P;Kennecke HF;Hamilton SR;Kopetz S;

More >>

Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience

Breast Cancer Res Treat , 2020
Dent SF;Botros J;Rushton M;Aseyev O;Levine MN;Parulekar WR;OGCOBrien P;Burnell M;Pritchard KI;Chen BE;Shepherd LE;

More >>

Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial (ONLINE)

Cancer n/a, 2020
Moku P;Shepherd L;Ali SM;Leitzel K;Parulekar WR;Zhu L;Virk S;Nomikos D;Aparicio S;Gelmon K;Drabick J;Cream L;Halstead ES;Umstead TM;Mckeone D;Polimera H;Maddukuri A;Ali A;Nagabhairu V;Poulose J;Pancholy N;Spiegel H;Chen BE;Lipton A;

More >>

The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance)

Cancer Epidemiol Biomarkers Prev 29: 1692, 2020
Cheng E;Zhang S;Ou FS;Mullen B;Ng K;Saltz LB;Niedzwiecki D;Mayer RJ;Mowat RB;Whittom R;Hantel A;Benson A;Atienza D;Messino M;Kindler H;Giovannucci EL;Van Blarigan EL;Meyerhardt JA;Fuchs CS;

More >>

Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial

The Lancet 396: 1413 - 1421, 2020
Parker CC;Clarke NW;Cook AD;Kynaston HG;Petersen PM;Catton C;Cross W;Logue J;Parulekar W;Payne H;Persad R;Pickering H;Saad F;Anderson J;Bahl A;Bottomley D;Brasso K;Chahal R;Cooke PW;Eddy B;Gibbs S;Goh C;Gujral S;Heath C;Henderson A;Jaganathan R;Jakobsen H;James ND;Kanaga Sundaram S;Lees K;Lester J;Lindberg H;Money-Kyrle J;Morris S;O'Sullivan J;Ostler P;Owen L;Patel P;Pope A;Popert R;Raman R;Roder MA;Sayers I;Simms M;Wilson J;Zarkar A;Parmar MKB;Sydes MR;

More >>